Evidence map›Paper›PMID 29757195›Full record

ReviewThe Journal of clinical investigation2018

Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators.

Charles N Serhan, Bruce D Levy

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of clinical investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04701138 (Bioavailability of Specialized Pro-resolving Mediators in Obese Humans), which is not on this map. Cited by 817 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
817citing papers in PubMed, 2 pooled it
79.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04701138 nacompletednot on this mapstarted 2021, after this paper: background citation

Bioavailability of Specialized Pro-resolving Mediators in Obese Humans

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2021 to 2021Enrolled24ConditionsObesity Adult OnsetArmsSPM Active
3 · Its place in the literature

Who cites it

817 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,244 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Innate immunity: current understandings and future perspectives.Signal transduction and targeted therapy · 2026
    Review

757 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Charles N SerhanCenter for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, and.
Bruce D LevyPulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Brigham and Women's Hospital · US

Funding

Resolution Mechanisms in Acute Inflammation: Resolution PharmacologyP01GM095467 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI PETASIS, NICOS A · 2011 to 2020
$14.8M
Specialized Pro-Resolving Mediators in AsthmaR01HL122531 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LEVY, BRUCE D · 2014 to 2024
$4.7M
NHLBI NIH HHS R01 HL122531NIGMS NIH HHS P01 GM095467
6 · The paper itself

Abstract

Countless times each day, the acute inflammatory response protects us from invading microbes, injuries, and insults from within, as in surgery-induced tissue injury. These challenges go unnoticed because they are self-limited and naturally resolve without progressing to chronic inflammation. Peripheral blood markers of inflammation are present in many common diseases, including inflammatory bowel disease, cardiovascular disease, neurodegenerative disease, and cancer. While acute inflammation is protective, excessive swarming of neutrophils amplifies collateral tissue damage and inflammation. Hence, understanding the mechanisms that control the resolution of acute inflammation provides insight into preventing and treating inflammatory diseases in multiple organs. This Review focuses on the resolution phase of inflammation with identification of specialized pro-resolving mediators (SPMs) that involve three separate biosynthetic and potent mediator families, which are defined using the first quantitative resolution indices to score this vital process. These are the resolvins, protectins, and maresins: bioactive metabolomes that each stimulate self-limited innate responses, enhance innate microbial killing and clearance, and are organ-protective. We briefly address biosynthesis of SPMs and their activation of endogenous resolution programs as terrain for new therapeutic approaches that are not, by definition, immunosuppressive, but rather new immunoresolvent therapies.

Indexed as

Adaptive ImmunityAnimalsArthritisBiomarkersDocosahexaenoic AcidsFatty Acids, UnsaturatedHumansImmunity, InnateInflammationInflammation MediatorsLipoxinsModels, BiologicalNeuroimmunomodulationNeutrophilsSignal TransductionBiomarkersDocosahexaenoic AcidsFatty Acids, UnsaturatedInflammation MediatorsLipoxins

Identifiers

PMID29757195
PMCPMC6025982
OpenAlexW2802901067

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.